Amgen, Genentech sign license agreements for antibody patents

By Angela McDaniels

Seattle, Jan. 26 - Amgen Inc. and Genentech Inc. said they have entered into several agreements that grant licenses to each other under multiple patents for the manufacture and use of antibodies and related technology.

These agreements include a grant by Genentech to Amgen of a license for multiple antibodies under the Cabilly patent family (U.S. patent No. 6,331,415 et al.) relating in part to methods of producing immunoglobulins.

Financial details of the license agreements were not disclosed.

Amgen is a biotechnology company based in Thousand Oaks, Calif., that develops human therapeutics.

Genentech is a South San Francisco, Calif.-based biotechnology company that develops and commercializes biotherapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.